Paul Baldrick

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3836686/publications.pdf

Version: 2024-02-01

40 papers	1,354 citations	394421 19 h-index	345221 36 g-index
41 all docs	41 docs citations	41 times ranked	1718 citing authors

#	Article	IF	Citations
1	The safety of chitosan as a pharmaceutical excipient. Regulatory Toxicology and Pharmacology, 2010, 56, 290-299.	2.7	460
2	Pharmaceutical Excipient Development: The Need for Preclinical Guidance. Regulatory Toxicology and Pharmacology, 2000, 32, 210-218.	2.7	84
3	Safety Evaluation of Monophosphoryl Lipid A (MPL): An Immunostimulatory Adjuvant. Regulatory Toxicology and Pharmacology, 2002, 35, 398-413.	2.7	83
4	Review ofL-tyrosine confirming its safe human use as an adjuvant. Journal of Applied Toxicology, 2002, 22, 333-344.	2.8	61
5	The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primates. Regulatory Toxicology and Pharmacology, 2012, 62, 347-354.	2.7	54
6	Safety evaluation to support first-in-man investigations II: Toxicology studies. Regulatory Toxicology and Pharmacology, 2008, 51, 237-243.	2.7	48
7	Developing drugs for pediatric use: a role for juvenile animal studies?. Regulatory Toxicology and Pharmacology, 2004, 39, 381-389.	2.7	43
8	Safety evaluation of biological drugs: What are toxicology studies in primates telling us?. Regulatory Toxicology and Pharmacology, 2011, 59, 227-236.	2.7	42
9	Juvenile animal testing in drug development â€“ Is it useful?. Regulatory Toxicology and Pharmacology, 2010, 57, 291-299.	2.7	40
10	Carcinogenicity Evaluation: Comparison of Tumor Data from Dual Control Groups in the Sprague â€“ Dawley Rat. Toxicologic Pathology, 2005, 33, 283-291.	1.8	36
11	Toxicokinetics in preclinical evaluation. Drug Discovery Today, 2003, 8, 127-133.	6.4	35
12	Carcinogenicity Evaluation: Comparison of Tumor Data from Dual Control Groups in the CD â€“ 1 Mouse. Toxicologic Pathology, 2007, 35, 562-575.	1.8	32
13	PollinexÂ® Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPLÂ®) for the treatment of ragweed pollen allergy. Journal of Applied Toxicology, 2007, 27, 399-409.	2.8	32
14	Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. MAbs, 2016, 8, 427-435.	5.2	32
15	Dose site reactions and related findings after vaccine administration in safety studies. Journal of Applied Toxicology, 2016, 36, 980-990.	2.8	30
16	Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPLÂ®) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine, 2001, 20, 737-743.	3.8	29
17	Reviewing the Utility of Two Species in General Toxicology Related to Drug Development. International Journal of Toxicology, 2018, 37, 121-124.	1.2	23
18	Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regulatory Toxicology and Pharmacology, 2014, 70, 413-429.	2.7	22

#	Article	IF	Citations
19	Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation. Regulatory Toxicology and Pharmacology, 2020, 113, 104624.	2.7	22
20	Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A(MPLÂ®) for the treatment of grass pollen allergy. Journal of Applied Toxicology, 2004, 24, 261-268.	2.8	20
21	Safety evaluation to support First-In-Man investigations I: Kinetic and safety pharmacology studies. Regulatory Toxicology and Pharmacology, 2008, 51, 230-236.	2.7	16
22	Getting a molecule into the clinic: Nonclinical testing and starting dose considerations. Regulatory Toxicology and Pharmacology, 2017, 89, 95-100.	2.7	16
23	The evolution of juvenile animal testing for small and large molecules. Regulatory Toxicology and Pharmacology, 2013, 67, 125-135.	2.7	14
24	Juvenile Animal Testing: Assessing Need and Use in the Drug Product Label. Therapeutic Innovation and Regulatory Science, 2018, 52, 641-648.	1.6	11
25	A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPLÂ®) for the treatment of grass pollen allergy. Journal of Applied Toxicology, 2012, 32, 608-616.	2.8	8
26	Pharmacokinetic and toxicology comparator testing of biosimilar drugs â€“ Assessing need. Regulatory Toxicology and Pharmacology, 2017, 86, 386-391.	2.7	8
27	Utility and importance of animal data in drug product labels. Regulatory Toxicology and Pharmacology, 2014, 69, 546-557.	2.7	7
28	Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies. Regulatory Toxicology and Pharmacology, 2021, 121, 104869.	2.7	7
29	Core battery safety pharmacology testing â€“ An assessment of its utility in early drug development. Journal of Pharmacological and Toxicological Methods, 2021, 109, 107055.	0.7	7
30	Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPLÂ®) for the treatment of grass pollen allergy. Reproductive Toxicology, 2011, 32, 322-328.	2.9	6
31	Development of COVID-19 therapies: Nonclinical testing considerations. Regulatory Toxicology and Pharmacology, 2022, 132, 105189.	2.7	5
32	Genotoxicity test battery â€“ An assessment of its utility in early drug development. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2021, 868-869, 503388.	1.7	4
33	Nonclinical safety testing of imaging agents, contrast agents and radiopharmaceuticals. Journal of Applied Toxicology, 2021, 41, 95-104.	2.8	3
34	Risk Management Plans in the European Union: Nonclinical Aspects. Therapeutic Innovation and Regulatory Science, 2016, 50, 101-105.	1.6	2
35	Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future. Therapeutic Innovation and Regulatory Science, 2019, , 216847901986455.	1.6	1
36	New toxicity testing of PQ grass allergy immunotherapy to support product development. Journal of Applied Toxicology, 2019, 39, 1462-1469.	2.8	1

#	Article	IF	Citations
37	Successful regulatory agency interaction â€“ A nonclinical regulatory strategist's perspective. Regulatory Toxicology and Pharmacology, 2022, 130, 105130.	2.7	1
38	Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development. Regulatory Toxicology and Pharmacology, 2019, 108, 104441.	2.7	0
39	Nonclinical Immunotoxicity Testing in the Pharmaceutical World: The Past, Present, and Future. Therapeutic Innovation and Regulatory Science, 2020, 54, 586-597.	1.6	0
40	Biological safety testing of polymers. Medical Device Technology, 2003, 14, 12-5.	0.1	0